Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.

Bianchi F, Veggi D, Santini L, Buricchi F, Bartolini E, Lo Surdo P, Martinelli M, Finco O, Masignani V, Bottomley MJ, Maione D, Cozzi R.

FASEB J. 2019 Aug 23:fj201900374R. doi: 10.1096/fj.201900374R. [Epub ahead of print]

PMID:
31442074
2.

Vaccine Evolution and Its Application to Fight Modern Threats.

Andreano E, D'Oro U, Rappuoli R, Finco O.

Front Immunol. 2019 Jul 25;10:1722. doi: 10.3389/fimmu.2019.01722. eCollection 2019. Review.

3.

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.

Giuliani M, Bartolini E, Galli B, Santini L, Lo Surdo P, Buricchi F, Bruttini M, Benucci B, Pacchiani N, Alleri L, Donnarumma D, Pansegrau W, Peschiera I, Ferlenghi I, Cozzi R, Norais N, Giuliani MM, Maione D, Pizza M, Rappuoli R, Finco O, Masignani V.

Sci Rep. 2018 Feb 27;8(1):3700. doi: 10.1038/s41598-018-22057-7.

4.

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.

Leroux-Roels G, Lattanzi M, Solis CD, Contorni M, Costantini M, Moraschini L, Bardelli M, Bertholet S, Borgogni E, Buricchi F, Cantisani R, Faenzi E, Finco O, Leuzzi R, Pizza M, Rosa D, Schiavetti F, Seubert A, Spensieri F, Volpini G, Zedda L, Giudice GD, Galgani I.

Hum Vaccin Immunother. 2018 Jan 2;14(1):45-58. doi: 10.1080/21645515.2017.1385686. Epub 2017 Nov 27.

5.

Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Systems Biology Views of Vaccine Innate and Adaptive Immunity.

Rappuoli R, Siena E, Finco O.

Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8). pii: a029256. doi: 10.1101/cshperspect.a029256. Review.

PMID:
29038117
6.

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.

Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, Maugard A, Marchetti E, Zancan S, Huo Z, Rondini S, Marhaba R, Finco O, Martin LB, Auerbach J, Cohen D, Saul A, Gerke C, Podda A.

EBioMedicine. 2017 Aug;22:164-172. doi: 10.1016/j.ebiom.2017.07.013. Epub 2017 Jul 15.

7.

Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.

Raymond DD, Stewart SM, Lee J, Ferdman J, Bajic G, Do KT, Ernandes MJ, Suphaphiphat P, Settembre EC, Dormitzer PR, Del Giudice G, Finco O, Kang TH, Ippolito GC, Georgiou G, Kepler TB, Haynes BF, Moody MA, Liao HX, Schmidt AG, Harrison SC.

Nat Med. 2016 Dec;22(12):1465-1469. doi: 10.1038/nm.4223. Epub 2016 Nov 7.

8.

Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design.

Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E.

J Exp Med. 2016 Apr 4;213(4):469-81. doi: 10.1084/jem.20151960. Epub 2016 Mar 28. Review.

9.

Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes.

Viciani E, Montagnani F, Tavarini S, Tordini G, Maccari S, Morandi M, Faenzi E, Biagini C, Romano A, Salerni L, Finco O, Lazzi S, Ruggiero P, De Luca A, Barocchi MA, Manetti AG.

Sci Rep. 2016 Feb 10;6:20609. doi: 10.1038/srep20609.

10.

B Cells and Functional Antibody Responses to Combat Influenza.

Lofano G, Kumar A, Finco O, Del Giudice G, Bertholet S.

Front Immunol. 2015 Jun 30;6:336. doi: 10.3389/fimmu.2015.00336. eCollection 2015. Review.

11.

Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination.

Lofano G, Mancini F, Salvatore G, Cantisani R, Monaci E, Carrisi C, Tavarini S, Sammicheli C, Rossi Paccani S, Soldaini E, Laera D, Finco O, Nuti S, Rappuoli R, De Gregorio E, Bagnoli F, Bertholet S.

J Immunol. 2015 Aug 15;195(4):1617-27. doi: 10.4049/jimmunol.1402604. Epub 2015 Jul 13.

12.

Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivo.

Nair N, Buti L, Faenzi E, Buricchi F, Nuti S, Sammicheli C, Tavarini S, Popp MW, Ploegh H, Berti F, Pizza M, Castellino F, Finco O, Rappuoli R, Del Giudice G, Galli G, Bardelli M.

Immun Inflamm Dis. 2013 Oct;1(1):3-13. doi: 10.1002/iid3.3. Epub 2013 Oct 30.

13.

Designing vaccines for the twenty-first century society.

Finco O, Rappuoli R.

Front Immunol. 2014 Jan 23;5:12. doi: 10.3389/fimmu.2014.00012. eCollection 2014. Review.

14.

Two cross-reactive monoclonal antibodies recognize overlapping epitopes on Neisseria meningitidis factor H binding protein but have different functional properties.

Faleri A, Santini L, Brier S, Pansegrau W, Lo Surdo P, Scarselli M, Buricchi F, Volpini G, Genovese A, van der Veen S, Lea S, Tang CM, Savino S, Pizza M, Finco O, Norais N, Masignani V.

FASEB J. 2014 Apr;28(4):1644-53. doi: 10.1096/fj.13-239012. Epub 2013 Dec 26.

PMID:
24371123
15.

Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro.

Bartolini E, Ianni E, Frigimelica E, Petracca R, Galli G, Berlanda Scorza F, Norais N, Laera D, Giusti F, Pierleoni A, Donati M, Cevenini R, Finco O, Grandi G, Grifantini R.

J Extracell Vesicles. 2013 May 6;2. doi: 10.3402/jev.v2i0.20181. eCollection 2013.

16.

Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses.

Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, Del Giudice G, Galli G, Castellino F.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14330-5. doi: 10.1073/pnas.1311998110. Epub 2013 Aug 12.

17.

Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus.

Buricchi F, Bardelli M, Malzone C, Capecchi B, Nicolay U, Fragapane E, Castellino F, Del Giudice G, Galli G, Finco O.

Eur J Immunol. 2013 Mar;43(3):641-8. doi: 10.1002/eji.201242563. Epub 2013 Jan 24.

18.

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.

Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecchi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G.

Vaccine. 2012 Jun 8;30(27):4086-94. doi: 10.1016/j.vaccine.2012.04.020. Epub 2012 Apr 19.

PMID:
22521851
19.

Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines.

Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E, Meoni E, Bonci A, Agnusdei M, Nardelli F, Bartolini E, Scarselli M, Caproni E, Laera D, Zedda L, Skibinski D, Giovinazzi S, Bastone R, Ianni E, Cevenini R, Grandi G, Grifantini R.

Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9969-74. doi: 10.1073/pnas.1101756108. Epub 2011 May 31.

20.

CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans.

Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S, Bonci A, Petracca R, Bartolini E, Galli G, Agnusdei M, Nardelli F, Buricchi F, Norais N, Ferlenghi I, Donati M, Cevenini R, Finco O, Grandi G, Grifantini R.

Infect Immun. 2009 Sep;77(9):4168-76. doi: 10.1128/IAI.00344-09. Epub 2009 Jul 13.

21.

Rediscovering complement, the first barrier of innate immunity.

Finco O, Rappuoli R.

Vaccine. 2008 Dec 30;26 Suppl 8:I1-2. No abstract available.

PMID:
19388156
22.

Invariant NKT cells sustain specific B cell responses and memory.

Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G, Abrignani S.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3984-9. Epub 2007 Feb 27.

23.

Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection.

Thorpe C, Edwards L, Snelgrove R, Finco O, Rae A, Grandi G, Guilio R, Hussell T.

Vaccine. 2007 Mar 8;25(12):2252-60. Epub 2006 Dec 13.

PMID:
17275142
24.

Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Baraldo K, Mori E, Bartoloni A, Norelli F, Grandi G, Rappuoli R, Finco O, Del Giudice G.

Infect Immun. 2005 Sep;73(9):5835-41.

25.

Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells.

Capo S, Nuti S, Scarselli M, Tavarini S, Montigiani S, Mori E, Finco O, Abrignani S, Grandi G, Bensi G.

Vaccine. 2005 Oct 10;23(42):5028-37. Erratum in: Vaccine. 2007 Apr 30;25(17):3516.

PMID:
15982792
26.

Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings.

Finco O, Bonci A, Agnusdei M, Scarselli M, Petracca R, Norais N, Ferrari G, Garaguso I, Donati M, Sambri V, Cevenini R, Ratti G, Grandi G.

Vaccine. 2005 Jan 19;23(9):1178-88.

PMID:
15629361
27.

Experimental infection by Chlamydia pneumoniae in the hamster.

Sambri V, Donati M, Storni E, Di Leo K, Agnusdei M, Petracca R, Finco O, Grandi G, Ratti G, Cevenini R.

Vaccine. 2004 Mar 12;22(9-10):1131-7.

PMID:
15003640
28.

Genomic approach for analysis of surface proteins in Chlamydia pneumoniae.

Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, Mariani M, Manetti R, Agnusdei M, Cevenini R, Donati M, Nogarotto R, Norais N, Garaguso I, Nuti S, Saletti G, Rosa D, Ratti G, Grandi G.

Infect Immun. 2002 Jan;70(1):368-79.

29.

Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines.

Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, Melli ML, Finco O, Wack A, Di Tommaso A, De Magistris MT, Costantino P, Del Giudice G, Abrignani S, Rappuoli R, Grandi G.

Eur J Immunol. 2001 Dec;31(12):3816-24.

30.

Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice.

Toneatto S, Finco O, van der Putten H, Abrignani S, Annunziata P.

AIDS. 1999 Dec 3;13(17):2343-8.

PMID:
10597775
31.

Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid.

Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kocken C, Thomas A, Abrignani S, Grandi G.

Eur J Immunol. 1998 Apr;28(4):1225-32.

32.

Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4.

Finco O, Nuti S, De Magistris MT, Mangiavacchi L, Aiuti A, Forte P, Fantoni A, van der Putten H, Abrignani S.

Eur J Immunol. 1997 Jun;27(6):1319-24.

PMID:
9209479
33.

Regulation of the B cell response to T-dependent antigens by classical pathway complement.

Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, Kremmer E, Rosen FS, Carroll MC.

J Immunol. 1996 Jul 15;157(2):549-56.

PMID:
8752901
34.

Neutral endopeptidase modulates septic shock.

Lu B, Gerard NP, Kolakowski LF Jr, Finco O, Carroll MC, Gerard C.

Ann N Y Acad Sci. 1996 Mar 22;780:156-63.

PMID:
8602728
35.

Neutral endopeptidase modulation of septic shock.

Lu B, Gerard NP, Kolakowski LF Jr, Bozza M, Zurakowski D, Finco O, Carroll MC, Gerard C.

J Exp Med. 1995 Jun 1;181(6):2271-5.

36.

Structural differences between the two human complement C4 isotypes affect the humoral immune response.

Finco O, Li S, Cuccia M, Rosen FS, Carroll MC.

J Exp Med. 1992 Feb 1;175(2):537-43.

37.

Polymorphisms of HLA class III genes in allergic contact dermatitis.

Orecchia G, Perfetti L, Finco O, Dondi E, Cuccia M.

Dermatology. 1992;184(4):254-9.

PMID:
1498391
38.

HLA markers in sarcoidosis.

Luisetti M, Martinetti M, Cuccia M, Pasturenzi L, Bulgheroni A, Finco O, Daielli C, Donnetta AM, Peona V.

Sarcoidosis. 1991 Sep;8(2):177. No abstract available.

PMID:
1669989
39.

HLA complement markers in Italian narcoleptic patients with special emphasis on BfF subtyping.

Cuccia M, Finco O, Conte R, Cirignotta F, Ruberto G.

Complement Inflamm. 1991;8(2):86-91.

PMID:
2055012
40.

Sarcoidosis and major histocompatibility complex genes with special emphasis on BF F subtypes.

Finco O, Martinetti M, Dondi E, Luisetti M, Pasturenzi L, Cuccia M.

Complement Inflamm. 1991;8(2):80-5.

PMID:
2055011
41.

Age of onset in vitiligo: relationship with HLA supratypes.

Finco O, Cuccia M, Martinetti M, Ruberto G, Orecchia G, Rabbiosi G.

Clin Genet. 1991 Jan;39(1):48-54.

PMID:
1997215
42.

Can C4AQO decreased frequency be considered a genetic marker for vitiligo and familial melanoma?

Orecchia G, Perfetti L, Cuccia M, Finco O.

Dermatologica. 1990;181(1):77-8. No abstract available.

PMID:
2394312

Supplemental Content

Support Center